Aurinia Pharmaceuticals Inc
NASDAQ:AUPH

Watchlist Manager
Aurinia Pharmaceuticals Inc Logo
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Watchlist
Price: 8.71 USD Market Closed
Market Cap: 1.2B USD
Have any thoughts about
Aurinia Pharmaceuticals Inc?
Write Note

Net Margin
Aurinia Pharmaceuticals Inc

-10.2%
Current
-114%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-10.2%
=
Net Income
-22.6m
/
Revenue
220.4m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
CA
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
1.2B USD
-10%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
320.1B USD
9%
US
Amgen Inc
NASDAQ:AMGN
147.4B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.3B EUR
-14%
Country CA
Market Cap 1.2B USD
Net Margin
-10%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 320.1B USD
Net Margin
9%
Country US
Market Cap 147.4B USD
Net Margin
13%
Country US
Market Cap 119.4B USD
Net Margin
-5%
Country US
Market Cap 113.8B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.4B AUD
Net Margin
18%
Country US
Market Cap 82.6B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.3B EUR
Net Margin
-14%
No Stocks Found

Aurinia Pharmaceuticals Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company is headquartered in Victoria, British Columbia and currently employs 300 full-time employees. The company went IPO on 2001-07-16. The firm is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The firm has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The company also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.

AUPH Intrinsic Value
12.02 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-10.2%
=
Net Income
-22.6m
/
Revenue
220.4m
What is the Net Margin of Aurinia Pharmaceuticals Inc?

Based on Aurinia Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -10.2%.